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Cysteine proteinases are key virulence factors of the protozoan parasite Entamoeba histolytica. We have shown that
cysteine proteinases play a central role in tissue invasion and disruption of host defenses by digesting components
of the extracellular matrix, immunoglobulins, complement, and cytokines. Analysis of the E. histolytica genome
project has revealed more than 40 genes encoding cysteine proteinases. We have focused on E. histolytica cysteine
proteinase 1 (EhCP1) because it is one of two cysteine proteinases unique to invasive E. histolytica and is highly
expressed and released. Recombinant EhCP1 was expressed in Escherichia coli and refolded to an active enzyme with
a pH optimum of 6.0. We used positional-scanning synthetic tetrapeptide combinatorial libraries to map the
specificity of the P1 to P4 subsites of the active site cleft. Arginine was strongly preferred at P2, an unusual specificity
among clan CA proteinases. A new vinyl sulfone inhibitor, WRR483, was synthesized based on this specificity to
target EhCP1. Recombinant EhCP1 cleaved key components of the host immune system, C3, immunoglobulin G,
and pro-interleukin-18, in a time- and dose-dependent manner. EhCP1 localized to large cytoplasmic vesicles,
distinct from the sites of other proteinases. To gain insight into the role of secreted cysteine proteinases in amebic
invasion, we tested the effect of the vinyl sulfone cysteine proteinase inhibitors K11777 and WRR483 on invasion of
human colonic xenografts. The resultant dramatic inhibition of invasion by both inhibitors in this human colonic
model of amebiasis strongly suggests a significant role of secreted amebic proteinases, such as EhCP1, in the
pathogenesis of amebiasis.
The intestinal protozoan parasite Entamoeba histolytica is the
etiologic agent of amebic colitis and liver abscess, which cause
high rates of morbidity and mortality worldwide (49). The mechanism by which Entamoeba histolytica is able to invade and damage the host’s target tissues has been the subject of intense research. Several virulence factors have been identified, including
secreted cysteine proteinases (39, 42). These amebic enzymes
have been implicated in the in vitro cytopathology of cell monolayers (20, 23), which correlates with the observed separation of
colonic epithelial cells before invasion (51). Other correlates with
invasion include the ability of cysteine proteinases to degrade
extracellular matrix components (19) and colonic mucin (31, 32).
Furthermore, cysteine proteinases enable E. histolytica to evade
the host’s immune defenses by activating and locally depleting
complement (43), and by degrading anaphylotoxins C3a and C5a

(41), human immunoglobulin G (IgG) (53), human IgA (21), and
interleukin-18 (IL-18) (37).
The recent completion of the Entamoeba histolytica genome
project has revealed the presence of at least 40 genes encoding
cysteine proteinases (25). Of all the cysteine proteinase genes,
only ehcp1 and ehcp5 are unique to E. histolytica, as their
orthologs are either absent (ehcp1) or nonfunctional (ehcp5) in
Entamoeba dispar, a morphologically identical but noninvasive
Entamoeba species (5, 6, 54). Surprisingly, only a small subset
of these genes are expressed in cultured Entamoeba histolytica
trophozoites (6), and only three, ehcp1, ehcp2, and ehcp5, account for more than 90% of the cysteine proteinase-specific
transcripts in culture (5, 6). Quantitative studies of the expression of the major Entamoeba histolytica cysteine proteinases
have shown that E. histolytica cysteine proteinase 1 (EhCP1) is
one of the most highly expressed and released cysteine proteinases in cultured trophozoites (6, 8, 17). In a recent study of
gene expression in a mouse model of amebic colitis, EhCP1
expression was increased almost twofold following invasion,
while expression of EhCP5, the other E. histolytica-specific
proteinase, was not (11). To further characterize this impor-
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MATERIALS AND METHODS
Entamoeba cultures and purification of genomic DNA. E. histolytica strain
HM1:IMSS was grown axenically in TYI-S-33 medium (9) and subcultured every
48 to 72 h. E. histolytica genomic DNA was purified from trophozoite nuclei with
the DNeasy Kit (QIAGEN, Valencia, CA).
Isolation and purification of released amebic cysteine proteinases. Released
proteinases in conditioned medium (CM) from Entamoeba histolytica trophozoites were prepared as previously described in phosphate-buffered saline supplemented with additional cysteine and divalent cations which maintained ⬎95%
viability (by trypan blue exclusion) (17).
Cloning, expression, and purification of EhCP1 in Escherichia coli. The sequence encoding the pro- and mature region of the E. histolytica EhCP1 gene
(accession no. M94164) was amplified from E. histolytica genomic DNA by PCR
(HotstartTaq Master Mix kit; QIAGEN, Valencia, CA) and cloned into the
pBAD/Thio-TOPO plasmid (Invitrogen, Carlsbad, CA), resulting in expression
of the recombinant protein as a thioredoxin fusion (amino terminus) with a
six-residue histidine tail (carboxy terminus). Expression was induced as previously described (36), except that 0.2% arabinose was used for 4 h. For antibody
production, rEhCP1 was expressed without the thioredoxin tail in the pRSETA
vector (Invitrogen, Carlsbad, CA) and purified under denaturing conditions over
nickel-nitrilotriacetic acid (36). Recombinant thio-pro-EhCP1 was purified from
frozen pellets as previously described (37) except that we used 6 M urea and a 20
to 500 mM imidazole gradient for elution from the HiTrap-Ni-chelating column.
Refolding and purification of thio-pro-EhCP1. The refolding of denatured
thio-pro-EhCP1 was tested under the screening conditions elucidated by Armstrong et al. (3) as we have previously modified them (38). The highest proteinase
activity was obtained by adding 1 M thio-pro-EhCP1 to 50 mM morpholineethanesulfonic acid, pH 6.0, 30 mM NaCl, 0.1% polyethylene glycol 4000, 10
mM EDTA, 750 mM arginine, 5 mM reduced glutathione, and 0.5 mM oxidized
glutathione for 48 to 72 h at 4°C. The proteinase was dialyzed against Trisbuffered saline, concentrated, and separated by ion-exchange fast-protein liquid
chromatography on a Hi-Trap-Q column (Amersham Biosciences, United
Kingdom).
Proteinase activity assay. The proteinase activity was determined by measuring the release of the fluorescent leaving group, 4-amino-7-methylcoumarin
(AMC), from synthetic peptide substrates (Bachem, Torrance, CA) in a Fluoroskan-Ascent fluorometer (Labsystems) (17). Enzyme activity, initial velocity,
and relative fluorescence units (RFU; the amount of proteinase activity needed
for the release of 1 pmol of AMC per minute) were calculated with Ascent
software. The Michaelis constant (Km) of rEhCP1 for the synthetic peptide
substrates Z-Arg-Arg-AMC and Z-Ala-Arg-Arg-AMC was determined with increasing concentrations of synthetic peptide substrates (0.5 to 20 M) using the
Enzfitter software (Biosoft, Cambridge, United Kingdom).
Production of Ab and immunoblot assays. Polyclonal antibodies (Abs) were
raised by immunizing rabbits subcutaneously three times with gel-purified rEhCP1
(100 g) mixed with TiterMax (Sigma, St. Louis, MO). The resulting immune
serum was absorbed with proteins from lysed E. coli cells coupled to cyanogen
bromide-activated Sepharose 4B. The absorbed serum IgG fraction was then
purified by protein A/G affinity chromatography (GE Health Care, Amersham
Biosciences, Pharmacia).
For immunoblots, rEhCP1 was electrophoresed by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred as previously described (40). Membranes were probed with monoclonal antithioredoxin
Ab (1:10,000; Invitrogen, Carlsbad, CA) or rabbit anti-rEhCP1 Ab (1:500) and
visualized with goat anti-mouse or anti-rabbit IgG-alkaline phosphatase
(1:10,000 dilution; Zymed, San Francisco, CA) (40).
Gelatin substrate gels. Refolded rEhCP1 was analyzed with the use of
gelatin substrate gels (12% polyacrylamide-SDS copolymerized with 0.1%

porcine gelatin) as previously described (37). Samples were incubated for 15
min in buffer or with 100 M E-64 prior to electrophoresis.
Substrate specificity of rEhCP1. Two synthetic combinatorial libraries were used
to determine the substrate specificities of the S1 to S4 subsites of active, purified
EhCP1 using a bifunctional fluorophore, 7-amino-4-carbamoylmethylcoumarin,
coupled to the peptides as previously described (15, 27). The P1 diverse library
consisted of 20 sublibraries with one native amino acid (cysteine was replaced by
norleucine) in the P1 position and the P2, P3, and P4 positions randomized with
equimolar mixtures of amino acids. To determine P2, P3, and P4 specificity, a
P1-lysine fixed library was used; the P2, P3, and P4 positions were spatially addressed
with 19 amino acids; and the remaining two positions were randomized.
pH profile of purified active rEhCP1. The pH optimum of rEhCP1 was determined by preincubating rEhCP1 (50 pmol) in standard assay buffer (17) for
pH 7.0 to 9.0 or with 25 mM sodium acetate for pH 4.0 to 6.5, and the remaining
enzymatic activity was determined as described above.
Cleavage of biologic substrates by purified, active rEhCP1. Human C3 (1 g;
Quidel, San Diego, CA) was incubated with increasing amounts of active purified
rEhCP1 or CM which was preincubated for 15 min at room temperature in buffer
alone or containing 80 M E-64 (an irreversible inhibitor of all cysteine proteinases) for 60 min at 37°C, and the cleavage products were analyzed by SDS-PAGE
as previously described (43). Cleavage of native human IgG (2 g; Sigma, St.
Louis, MO) was performed under similar conditions except for 16-h incubation.
The resulting immunoblots were probed with goat anti-human IgG–horseradish
peroxidase conjugate (1:20,000; Zymed, San Francisco, CA) and developed with
SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL). Human pro-IL-18 was expressed in E. coli as previously detailed (22, 37) and
incubated with increasing amounts of purified active rEhCP1, active rEhCP5
(expressed in Pichia pastoris [37]), or E. histolytica released proteinases for 1 to
3 h at 37°C, and the cleavage products were detected on immunoblots as previously described (37).
Intracellular localization of EhCP1. For confocal microscopy, E. histolytica
trophozoites were fixed in 10% formalin, permeabilized in 0.1% Triton X-100,
and detected with a mouse monoclonal Ab to EhCP3 (1:200) and a polyclonal
rabbit Ab to EhCP1 (1:200), as previously described (36). For immunoelectron
microscopy, trophozoites were fixed in 1% glutaraldehyde-4% paraformaldehyde
and then processed and embedded in glycol-metacrylate (24). Ultrathin sections
were reacted with rabbit polyclonal EhCP1 Ab (1:200) and mouse monoclonal
anti-EhCP3 (1:200) Ab and detected with anti-rabbit IgG conjugated with gold
particles (15-nm diameter; Ted Pella Inc., Redding, CA) and/or anti-mouse IgG
conjugated with gold particles (20-nm diameter). Sections were contrasted with
uranyl acetate and lead citrate and viewed under a Zeiss EM910 transmission
electron microscope.
Inhibition of rEhCP1 and released proteinases by cysteine proteinase inhibitors. K11777 is a vinyl sulfone inhibitor (N-methylpiperazine-urea-phenylalanylhomophenylalanyl-vinylsulfone-benzene), which has been shown to inhibit a
number of protozoan cysteine proteinases (10, 26) and has undergone extensive
toxicity testing (1). WRR483 was synthesized as a K11777 derivative with an
arginine substituted for phenylalanine at the P2 position. Kinetic analyses of the
irreversible cysteine protease inhibitors (4, 52) were performed by adding
rEHCP1 (20 to 30 nM) to 10-fold dilutions of inhibitor (500 nM to 100 M) with
10 M Z-Arg-Arg-AMC (Km ⫽ 2 M) on a Flex Station with robotics (Molecular Devices) and an 0.7-s read time. The value of kobs, the rate constant for loss
of enzyme activity, was determined from an equation for pseudo-first-order
dynamics using Prism 4 (GraphPad). When kobs varied linearly with inhibitor
concentration, Kass was determined by linear regression analysis (4). If the
variation was hyperbolic, indicating saturation inhibition kinetics, kinact and Ki
were determined from an equation describing a two-step irreversible inhibitor
mechanism {kobs ⫽ kinact [I]o/([I]o ⫹ Ki 䡠 (1 ⫹ [S]o/Km) } and nonlinear regression analysis using Prism (4).
Amebic infection of a human intestinal xenograft model. Human intestinal
xenografts were transplanted subcutaneously into the backs of SCID mice and
infected with E. histolytica trophozoites as previously detailed (28, 46, 55).
Xenografts were injected with medium alone, E. histolytica trophozoites (1 ⫻
106) in medium, or trophozoites preincubated with K11777 (20 M final concentration) or WRR483 (10 M final concentration). These conditions blocked
all detectable cysteine proteinase activity in trophozoites for ⬎24 h (data not
shown). A total dose of 1.5 mg of either inhibitor was administered intraperitoneally to each mouse (10). The xenografts were harvested at 24 h, the mucus plug
was removed, and sections were frozen in liquid nitrogen for DNA extraction or
fixed for histology. The presence of an intact muscularis layer and complete
removal of the mucus plug were confirmed in each experimental xenograft.
Quantification of amebic invasion in human intestinal xenografts. We developed a sensitive, quantitative real-time PCR assay to measure amebic invasion in
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tant amebic cysteine proteinase, we have cloned, expressed,
and refolded recombinant EhCP1 (rEhCP1) to obtain active
proteinase. We now show that rEhCP1 can cleave physiologic
substrates, such as the third component of complement, proIL-18, and IgG, components of the host immune response
which must be circumvented for the amebae to invade. We
designed a new inhibitor based on the marked preference of
EhCP1 for arginine in the P2 position. We now show for the
first time that specific inhibitors of cysteine proteinases block
invasion in the human colon.
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sequences (56). Xenograft DNA (0.1 ng) was amplified with 100 nM of sense (5⬘
ACG CCT GTA ATC CCA GCA CTT 3⬘) and antisense (5⬘ TCG CCC AGG
CTG GAG TGC A 3⬘) human Alu primers, under the same PCR conditions as
described above. Negative controls, positive controls, and the experimental samples were run in duplicate. The threshold cycle values from each sample were
averaged, and the standard deviation was calculated.

RESULTS

xenografts infected with E. histolytica. A standard curve to measure the number
of E. histolytica trophozoites invading human intestinal xenografts was generated
by adding trophozoites (102 to 106) to 25 to 50 mg of human intestinal xenograft
tissue and extracting the DNA with the PUREGENE DNA purification kit
(Gentra Systems, Minneapolis, MN). Real-time PCRs were carried out using the
SYBR green PCR Master Mix (Applied Biosystems, Foster City, CA) with 100
ng of the extracted DNA (from xenografts and standards) and 100 nM (final
concentration) of both the forward primer (5⬘-AAATCAATTGTGAAGTTAT
TGGAGTGA-3⬘) and the reverse primer (5⬘-TCCTACTCCTCCTTTACTTTT
ATCTGCT-3⬘), to amplify a 92-bp region of the E. histolytica peroxiredoxin gene
(7). Real-time PCR was performed under conditions previously described (40)
with a standard curve and negative controls consisting of reaction mixtures
without template or containing noninfected xenograft DNA (100 ng).
The potential presence of any PCR inhibitor in each of the human intestinal
xenograft DNA samples was tested by the quantitative measure of amplifiable
human genomic DNA with primers specific for the detection of human Alu

FIG. 2. Substrate specificity determined by synthetic combinatorial libraries. A P1 complete diverse library and P2, P3, and P4 sublibraries of
the P1-lysine fixed library were used to determine the substrate specificities of EhCP1. Activities are displayed as percentages of the maximum at
each position. Amino acids are represented by the single-letter code (“n” is norleucine). Error bars represent the standard deviations from the
results of duplicate experiments.
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FIG. 1. Purification of recombinant thio-pro-EhCP1 and refolded,
active rEhCP1. Recombinant thio-pro-EhCP1 was purified by Ni affinity chromatography, analyzed by 12% SDS-PAGE, and visualized by
Coomassie blue staining (lane 1), probing of an immunoblot with
polyclonal rabbit anti-EhCP1 Ab (lane 2), and probing of an immunoblot with mouse monoclonal antithioredoxin Ab (lane 3). Hi-TrapQ-purified, refolded, and active EhCP1 was analyzed by SDS-PAGE
(12% gels, silver stained) (lane 4), gelatin zymography (12% SDSPAGE, 0.1% gelatin, run under nonreducing conditions) (lane 5), and
immunoblotting (rabbit polyclonal anti-EhCP1 Ab) (lane 6). Numbers
at left are molecular masses in kilodaltons.

Expression, purification, and refolding of thio-pro-EhCP1.
Expression of the thio-pro-EhCP1 recombinant protein in E.
coli resulted in an overexpressed protein of ⬃50 kDa, corresponding to the predicted molecular mass for thio-pro-EhCP1
of 50.3 kDa (36.3 kDa for the zymogen form of EhCP1, 13 kDa
for the thioredoxin peptide, and 0.9 kDa for the six-His tag)
(Fig. 1). rEhCP1 was purified by nickel affinity chromatography
and reacted with rabbit polyclonal anti-EhCP1 Ab and monoclonal antithioredoxin Ab (Fig. 1).
The optimal refolding conditions to produce active rEhCP1
were determined by using a 16-condition screen as previously
reported (3, 38). The most effective conditions were identified
by cleavage of the synthetic peptide substrate Z-Arg-ArgAMC. Refolded rEhCP1 was unique in several ways. (i) Refolded rEhCP1 did not require preincubation at low pH, which
is usually required for the self-activation from the proform to
the mature form of eukaryotic cysteine proteinases. (ii) Refolded rEhCP1 could be activated in a Tris-EDTA, phosphateEDTA, or citrate-EDTA buffer at neutral or slightly alkaline
pH (7.0 to 7.5) with 2 to 5 mM dithiothreitol (DTT). (iii)
Refolded rEhCP1 could be activated with 5 to 10 mM cysteine
alone. rEhCP1 activation by cysteine is of importance as it
would not affect the in vitro cleavage of several of its putative
biological substrates, particularly C3, which is readily denatured in the presence of other thiol-reducing agents such as
DTT (43) or 2-mercaptoethanol, each of which is widely used
for the in vitro activation of cysteine proteinases.
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FIG. 3. Cleavage of biological substrates by rEhCP1. (A) Human
complement component C3 (1 g) was incubated with rEhCP1 (0 to
600 RFU) or Hi-Trap-Q-purified HM1 CM (50 RFU) for 60 min at
37°C, analyzed by SDS-PAGE, and stained with Coomassie blue. Both
native and recombinant proteinases cleaved the ␣ to an ␣⬘ chain, which
was inhibited by preincubation with E-64. (B) Human IgG (2 g) was
digested with CM or purified rEhCP1 (1,400 RFU) for 16 h at 37°C,
and the resulting immunoblots were probed with goat anti-human
IgG–horseradish peroxidase conjugate. The cleavage was inhibited by
preincubating the proteinases with E-64. The heavy (H) and light
(L) chains of IgG are indicated on the right. (C) Recombinant proIL-18 (0.4 g) was incubated for 1 h at 37°C in buffer alone, native
proteinases from CM (750 RFU), or 200 to 800 RFU of rEhCP1. The
degradation of pro-IL-18 was completely inhibited by preincubation
with E-64. Molecular weights (in thousands) are labeled at the left of
each panel.

Refolded active rEhCP1 was purified by ion-exchange
chromatography with a Hi-Trap-Q column (Amersham Biosciences, United Kingdom). As shown in Fig. 1, analysis of the
peak fractions revealed the presence of one polypeptide band
with a molecular mass of ⬃31 kDa shown by silver staining of
12% SDS gels, gelatin zymography, and probing of Western
blots with polyclonal anti-EhCP1 Ab. The active recombinant
enzyme ran true to Mr, even on gelatin gels, in contrast to
findings by Hellberg et al. (16), who found that a gelatinolytic
band of ⬃48 kDa had the same N-terminal peptide sequence
as did mature EhCP1.
Substrate specificity of rEhCP1. The preliminary substrate
specificity of refolded, active rEhCP1 was determined with
fluorogenic peptide substrates. Z-Arg-Arg-AMC and Z-Ala-

Arg-Arg-AMC, typical cathepsin B substrates, were readily
cleaved, whereas Z-Phe-Arg-AMC, a typical cathepsin L substrate, was not (data not shown). To further define the substrate requirements of rEhCP1, we mapped the specificity of
the rEhCP1 active site using two synthetic tetrapeptide combinatorial libraries (Fig. 2). An almost absolute requirement
for arginine at the P2 position was found.
pH optimum of rEhCP1. rEhCP1 was found to have a pH
optimum of 6.0, retaining most of its catalytic activity in the pH
range of 5.5 to 7.5 (data not shown). A 50% or higher reduction in the catalytic activity is seen at pH values of ⱕ5.0
or ⱖ8.0.
Biological substrate specificity of rEhCP1. To determine if
rEhCP1 had the same biological substrate specificity as the
secreted native proteinases, human C3, IgG, and pro-IL-18
were incubated with equal amounts of active purified rEhCP1
or native Eh-secreted proteinases (CM). rEhCP1 cleaves C3 in
a fashion identical to that of the secreted native proteinases
(43), generating the ␣⬘ subunit (Fig. 3A). rEhCP1 also cleaves
the human IgG heavy chain in a dose- (Fig. 3B) and timedependent manner (53) (data not shown), similar to native
proteinases. Human pro-IL-18 is also cleaved by rEhCP1, similar to the degradation seen by released amebic proteinases
(CM) and rEhCP5 (Fig. 3C) (37).
Intracellular localization of EhCP1. In order to determine
the intracellular localization of EhCP1, Entamoeba histolytica
trophozoites were labeled with rabbit polyclonal anti-EhCP1
Ab and imaged by fluorescence, confocal, and electron microscopy. EhCP1 localizes within large cytoplasmic vesicles,
which are distinct from those containing EhCP3 (Fig. 4A).
These results were confirmed by immunoelectron microscopy (Fig. 4B).
Inhibition of EhCP1 by vinyl sulfone inhibitors. We first
tested the inhibition of purified rEhCP1 by K11777, a vinyl
sulfone inhibitor which has been shown to cure Trypanosoma
cruzi infection in animals (10), has undergone extensive toxicity
testing (1), and is approaching clinical trials for Chagas’ disease. The Kass (kinact/Ki app) of K11777 against EhCP1 was 350
(1/M 䡠 1/s). We next synthesized a peptidomimetic vinyl sulfone with an arginine substituted for phenylalanine in the P2
position based on the distinct specificity for arginine in P2
detected by active site mapping (Fig. 2). The resulting Kass for
WRR483 was 849,000 (1/M 䡠 1/s), an increase of ⬃2,500-fold.
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FIG. 4. Localization of EhCP1. EhCP1 was localized in amebic
trophozoites by confocal microscopy (A) using polyclonal Ab to
EhCP1 (green) and monoclonal Ab to EhCP3 (red). These results
were confirmed by immunoelectron microscopy (B) where EhCP1
(15-nm gold particles) was present in large vesicles, distinct from
EhCP3 (20-nm gold particles).
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Effect of the cysteine proteinase inhibitors K11777 and
WRR483 on amebic invasion in the intestinal xenograft model.
We next tested the efficacy of the inhibitors in an in vivo model
of invasion of human intestine. The pathology of human colon
xenografts infected for 24 h with virulent E. histolytica trophozoites closely mimics human disease, with undermined ulcers
containing trophozoites interspersed with normal mucosa (Fig.
5, left). When colon xenografts were infected with E. histolytica
trophozoites preincubated with the cysteine proteinase inhibitor K11777 (1) (data not shown) or WRR483 (Fig. 5, right), no
invasion was seen. Amebic invasion in human colon xenografts
was quantified by a real-time PCR assay that could detect as
few as 10 trophozoites (data not shown). The amplification of
human Alu sequences in all of the xenografts was equivalent
(15.93 ⫾ 1.3) (56). Xenografts infected with E. histolytica trophozoites preincubated with the specific irreversible vinyl sulfone cysteine proteinase inhibitor K11777 had a ⬎80% reduction in the number of detectable E. histolytica trophozoites
(Fig. 6A). Inhibition of amebic invasion with the vinyl sulfone
cysteine proteinase inhibitor WRR483 was even more dramatic, with a ⬎95% reduction in the number of detectable
trophozoites in the xenograft tissue (Fig. 6B).
DISCUSSION
Released cysteine proteinases play a fundamental role in
invasion of target tissues by E. histolytica trophozoites. Analysis
of the E. histolytica genome reveals that 40 genes encode cysteine proteinases (25). Studies of the expression of the cysteine
proteinase genes have shown that only three, ehcp1, ehcp2, and
ehcp5, account for more than 90% of the cysteine proteinasespecific transcripts (5, 6) and more than 95% of secreted amebic proteinases in vitro (6, 8, 17). We focused on EhCP1 because it is unique to E. histolytica, there being no homologous
gene in the closely related but noninvasive E. dispar (5). It is
also one of the most highly expressed and released cysteine
proteinases (16, 17). Because of the difficulty in separating the
large number of similar native cysteine proteinases, we focused

FIG. 6. Quantification of amebic invasion in colonic xenografts. Human intestinal xenografts were infected with 1 ⫻ 106 Entamoeba histolytica trophozoites which had been preincubated in the presence or absence of 20 M specific irreversible cysteine proteinase inhibitor K11777
(A) or 10 M of WRR483 (B). At 24 h of incubation the xenografts were
harvested and DNA was extracted from 100 mg of xenograft tissue. The
amount of E. histolytica trophozoites present in each sample of tissue was
determined by a real-time PCR assay using a standard curve which related
the number of E. histolytica trophozoites to the cycle threshold. Values
represent the means ⫾ standard errors of duplicates from three xenograft
experiments.

on the expression of active, recombinant enzyme. We have
previously expressed active EhCP2 and EhCP3 in baculovirus
(36) and EhCP5 in Pichia (37). We expressed the proenzyme of
EhCP1 in E. coli as a thioredoxin fusion with a 3⬘ histidine tag
which autocatalytically processed itself to the mature, active
enzyme during refolding (Fig. 1). Surprisingly, purified, refolded rEhCP1 did not require activation by preincubation at
low pH or with thiol reagents, such as DTT, 2-mercaptoethanol, or cysteine, which distinguishes rEhCP1 from previously
purified recombinant parasite cysteine proteinases (16, 33,
44, 45, 47, 48). Purified refolded rEhCP1 has a pH optimum
of 6.0, although 50% or more of its catalytic activity is
retained across a pH range of 5.0 to 8.5. This broad pH
range is consistent with the release of native EhCP1 in the
neutral environment of the large bowel (29).
We have shown previously by homology modeling that the
structures of EhCP2, EhCP3, and EhCP5 are characteristic of
cathepsin L proteins with the ERFNIN motif, but their ability
to accept positively charged amino acids at P2 resembles
cathepsin B proteins (36). To further investigate this peptide
substrate preference, we mapped the specificity of the active site
cleft of rEhCP1 using two positional-scanning synthetic tetrapeptide combinatorial libraries (15, 27). We found an almost absolute
preference for arginine at the P2 position (Fig. 2), an unusual
specificity among clan CA proteinases. We took advantage of this
unique substrate specificity to design a vinyl sulfone inhibitor,
WRR483, from the scaffold compound K11777.
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FIG. 5. Pathology of invasion of E. histolytica in human intestinal
xenografts. Sections of intestinal xenografts of human colon in SCID mice
24 h following luminal injection of 1 ⫻ 106 Entamoeba histolytica (HM1)
trophozoites are shown. (Left) Acute inflammatory infiltrate and undermining of the mucosa in infected xenografts. The lumen is filled with
proteinaceous debris and clumps of trophozoites (closed arrows). Neutrophils (mouse) are shown with open arrowheads. (Right) Xenografts
from mice treated with the cysteine proteinase inhibitor WRR483 showed
no evidence of invasion (hematoxylin and eosin stain).
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hibitor blocks amebic invasion of the human colon by more
than 80% (Fig. 6A).
We next tested the new vinyl sulfone inhibitor WRR483,
which was synthesized with arginine at the P2 position instead
of phenylalanine to specifically target EhCP1. This specific
inhibitor was almost 2,500-fold more potent than K11777
against rEhCP1 (849,000 1/M 䡠 1/s). WRR483 is even more
effective than K11777 at blocking amebic invasion in the human intestinal xenograft model (Fig. 5, right), as it reduced
invasion by more than 95% (Fig. 6B).
Cysteine proteinases are an attractive target for agents designed to disrupt invasion by E. histolytica. The unique requirement of EhCP1 for arginine in the P2 position and the demonstrated ability of a specific cysteine proteinase inhibitor with
these particular structural features (WRR483) to block amebic
invasion of the bowel support the feasibility of this approach.
We have now shown that the expression of active recombinant
enzymes will enable us to dissect the role of individual cysteine
proteinases in the virulence of this important protozoan parasite. Also, these recombinant enzymes will be a fundamental tool
as we address the question of whether E. histolytica releases a
higher level of cysteine proteinases facilitating invasion, in contrast to noninvasive E. dispar, or whether the key determinants of
its invasiveness are the unique proteinases, EhCP1 and EhCP5.
We expect that our continuing efforts in specific inhibition of
these unique proteinases will shed yet more light on their roles in
the pathogenesis of amebiasis. In the meantime, our current studies have proven that inhibition of amebic cysteine proteinases
blocks invasion of the human bowel and have identified a promising, orally available scaffold inhibitor.
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